PharmTech provides information related to pharmaceutical technology, including drug development, manufacturing, and quality systems. It offers insights and resources on various topics in the pharmaceutical industry.

PharmTech

Pharma Now is a monthly B2B magazine that covers trends, technological innovations, and insights in the pharmaceutical and biopharmaceutical sectors. It provides industry news and updates, interviews with leaders, market insights, and regulatory updates.

Pharma Now

Media Production

MJH Life Sciences®

Pharmaceutical Technology | 5,137 followers on LinkedIn. Bringing you the latest in global pharmaceutical development and manufacturing industry. | Pharmaceutical Technology is the authoritative source of peer-reviewed research and expert analyses for scientists, engineers, and managers engaged in process development, manufacturing, formulation and drug delivery, API synthesis, analytical technology and testing, packaging, IT, outsourcing, and regulatory compliance in the pharmaceutical and biotechnology industries.

Susan Schniepp

Professor (Tenured)

Dr. Heidi M. Mansour, Ph.D. RPh, FAIMBE, SMNAI

Eastern Sales Manager; Pharmaceutical Technology and Pharmaceutical Technology Europe

Joel Kern

Independent Pharmaceuticals Professional

Katharina Picker-Freyer

Pharmaceutical Technology

Presidential election ramifications for pharmaceuticals - when full episode is ready next week, see it here: https://lnkd.in/eV6CBDw7 on 'Behind the Headlines" episode 6. Hearty thanks to Brian Feth CEO at xcellbio Biosciences and Jonathan D. Grinstein, PhD North America Editor for Inside Precision Medicine We talked about a host of topics that included investor sentiment, FDA and Centers for Disease Control and Prevention streamlining, In vitro fertilization's future, U.S. Department of Health and Human Services (HHS) leadership, - not to mention #CGT therapies, and the Interius BioTherapeutics First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies, alongside Autolus Therapeutics lupus treatment. BioPharm International Pharmaceutical Technology MJH Life Sciences®

Chris Spivey

Join Experts from Vectura Group to discuss how biologic formulations can be tailored and refined for lung delivery, whether in liquid or dry powder format. Save your seat: https://ow.ly/pILj50TYqTQ

The product license holder must have a supplier oversight system in place, says Siegfried Schmitt, PhD, vice president, Technical, Parexel. https://lnkd.in/eS8UaZ7r

I joined Chris Spivey and the #behindtheheadlines crew for a look into the crystal ball....and lots to talk about. My hot takes on what the election means for biopharma are below - comments welcome! 1) Taxes: Trump is likely to favor stock market-friendly policies like reinstating tax cuts and lowering corporate taxes, pushing the IPO window open further, boosting investment 2) Spending: Some analysts think Trump will advocate to control federal spending. I actually don’t think he has an appetite for that. Trump's record leans toward high spending to drive popularity. Expect continued spending, with a likely rise in XBI over the next few years. 3) Inflation: A safe bet from his first presidency is that he will lean heavily on the Fed to reduce interest rates rapidly - great for biopharma in the short term, but risks economic overheating and a return to rising inflation 4) FTC regulation: Likely reduced FTC oversight, encouraging M&A activity. Lina Khan may be replaced quickly. 5) FDA regulation: Expect an attempt to control and likely restructure, particularly with Elon Musk leading a government efficiency commission. However, many decisions are made by career staff, buffering extreme changes. 6) HHS Leadership: Trump’s leadership picks may be unconventional, very possibly affecting evidence-based policies. He has promised to let RFK Jr. “go wild” on drug and food policy. Howard Lutnick, co-chair of Trump’s transition team, said on CNN that Kennedy was “not getting a job for HHS.” If he does, I think it will be short lived. Still a really bad situation. 7) Drug price negotiations / Inflation Reduction Act (IRA): The president-elect’s prior "Most Favored Nation" drug pricing policy died after attracting lawsuits. I suspect he will depriotize price controls and instead focus on PBMs as a way to drive down drug prices. 8) BioSecure Act: Trump likely supports this amid U.S.-China tensions. Unfortunately China is a big market, provides low cost preclinical and clinical services, and has become a source of high quality therapeutic leads. Access may be (deeply) affected. 9) Affordable Care Act: Repeal unlikely, but JD Vance has suggested letting insurers divide enrollees into different risk pools - could mean lower costs for some but higher costs for sicker patients. 10) Chronic disease focus: Trump aims to focus on chronic disease with a presidential commission, echoing RFK's focus on metabolic syndrome-related indications in the “Make America Healthy Again” platform. 11) Medicaid: Trump will likely revisit work requirements for Medicaid, though prior efforts faced legal challenges. Some states still have lawsuits fighting for this. 12) Reproductive rights: There's likely no polling benefit to further limits. He might find a way to force funding of IVF via insurance

Brian Feth

Avid Bioservices has entered into a merger agreement, valued at approximately $1.1 billion, with GHO Capital Partners and Ampersand Capital Partners. https://lnkd.in/e3pTD626

Gain insights on the science behind solubility enhancement using the Dispersome® technology in this live virtual event sponsored by Zerion Pharma and Hovione . Register now: https://lnkd.in/gSixXCpp

Check out this upcoming live webcast from Pharmaceutical Technology® to explore how biologic drugs, traditionally developed for injectable use, can be optimized for lung delivery through innovative formulation strategies. #Biologics #Formulation

Recognize the role of excipients in stabilization of biologic APIs with experts from Lonza in this live virtual event. Register now: https://lnkd.in/eciYKiHD

Join us as we explore a lively discussion focused on cell and gene therapy topics in a recent Buy, Sell, Hold panel featured on BioPharm International . In part 1, Cellares co-founder and CEO, Fabian Gerlinghaus , joins a notable group of experts, including Dr. Claudia Zylberberg , Board Chair and Co-Founder of Arscience Biotherapeutics & Board Chair and Co-Founder of Akron Biosciences, and Benjamin McLeod , Director, Cell & Gene Therapy Segment, NanoMosaic, to discuss critical topics ranging from the importance of focusing on orphan diseases to the impact AI and quantum computing will have on innovation. Don't miss out on this valuable exchange of knowledge and innovation. View the full panel discussion here: https://lnkd.in/e5kRVRwV

Metric
Company Name	PharmTech	Pharma Now
Symbol
MSH ID	COM:PHARMTECH	LIVE:PHARMANOW
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Consumer Services
Industry	Pharmaceuticals	Pharmaceuticals
Country	US	IN
Stage
Employee Count
Website	pharmtech.com	pharmanow.live
LinkedIn	pharmaceutical-technology	pharma-now
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	31.16K
Web Traffic Growth	0.03
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

PHAR

COM:PHARMTECH

PharmTech

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue